EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Defining triple‐negative breast cancer with neuroendocrine differentiation ( TNBC‐NED )

Sean M Hacking, Evgeny Yakirevich, Yihong Wang

The Journal of Pathology: Clinical Research · 2023

DOI: 10.1002/cjp2.318 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2023. Verfasst von Sean M Hacking und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, Canada. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary breast neuroendocrine (NE) neoplasms are uncommon, and definitions harbor controversy. We retrospectively collected 73 triple‐negative breast cancers (TNBC) and evaluated NE biomarker expression along with p53 aberrant staining (which correlates with TP53 gene mutation) and Rb protein loss by immunohistochemistry. In the study cohort, we found 11 (15%) cases of TNBC with neuroendocrine differentiation (TNBC‐NED) showing positivity for one or more NE markers (synaptophysin/chromogranin/insulinoma‐associated protein 1 [INSM1]). We also identified one separate small cell neuroendocrine carcinoma. Histologic types for these 11 TNBC‐NED cases were as follows: 8 invasive ductal carcinoma (IDC) not otherwise specified (NOS), 2 IDC with apocrine features, 1 IDC with solid papillary features. INSM1 had the highest positivity and was seen in all 11 carcinomas. Seven (64%) cases showed p53 aberrant staining, 6 (55%) had Rb protein loss, while 6 (55%) had p53/Rb co‐aberrant staining/protein loss. TNBC‐NED was associated with Rb protein loss ( p < 0.001), as well as p53/Rb co‐aberrant staining/protein loss ( p < 0.001). In 61 cases negative for NE markers, 37 (61%) showed p53 aberrant staining, while 5 (8%) had Rb protein loss. We also analyzed genomic and transcriptomic data from The Cancer Genome Atlas (TCGA) PanCancer Atlas of 171 basal/TNBC patients. Transcriptomic analysis revealed mRNA expression of RB1 to be correlated negatively with SYN1 mRNA expression ( p = 0.0400) and INSM1 mRNA expression ( p = 0.0106) in this cohort. We would like to highlight the importance of these findings. TNBC‐NED is currently diagnosed as TNBC, and although it overlaps morphologically with TNBC without NED, the unique p53/Rb signature highlights a genetic overlap with NE carcinomas of the breast.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNeuroendocrine TumorsCarcinoma, NeuroendocrineCarcinoma, Ductal, BreastHumansBiomarkers, TumorTumor Suppressor Protein p53Retinoblastoma ProteinRetrospective StudiesCell DifferentiationRNA, MessengerRepressor Proteins

Stichwörter der Autor:innen

RB1TNBC-NEDTP53breastcarcinomaneuroendocrine

Substanzen

Biomarkers, TumorTumor Suppressor Protein p53Retinoblastoma ProteinRNA, MessengerINSM1 protein, humanRepressor Proteins

Autor:innen und Institutionen

  • Laboratory Medicine Program, University Health Network, Toronto General Hospital, Toronto, Canada.
  • Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, RI, USA.
  • Department of Pathology and Laboratory Medicine, Warren Alpert Medical School of Brown University, Providence, RI, USA.

Zitieren

APA

Hacking, S. M., Yakirevich, E., & Wang, Y. (2023). Defining triple‐negative breast cancer with neuroendocrine differentiation ( TNBC‐NED ). The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.318

Vancouver

Hacking SM, Yakirevich E, Wang Y. Defining triple‐negative breast cancer with neuroendocrine differentiation ( TNBC‐NED ). The Journal of Pathology: Clinical Research. 2023. doi:10.1002/cjp2.318

BibTeX
@article{Hacking2023,
  author = {Hacking, Sean M and Yakirevich, Evgeny and Wang, Yihong},
  title = {Defining triple‐negative breast cancer with neuroendocrine differentiation ( TNBC‐NED )},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2023},
  doi = {10.1002/cjp2.318}
}
Kostenlos starten →